Evoke Pharma (NASDAQ:EVOK) Major Shareholder Sells $95,850.00 in Stock

Evoke Pharma, Inc. (NASDAQ:EVOK) major shareholder Roger Klein sold 9,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.65, for a total transaction of $95,850.00. Following the sale, the insider directly owned 29,000 shares in the company, valued at approximately $308,850. This represents a 23.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Evoke Pharma Trading Up 0.6%

Shares of NASDAQ EVOK traded up $0.06 during midday trading on Friday, reaching $10.69. The company had a trading volume of 53,929 shares, compared to its average volume of 760,464. The business’s 50-day simple moving average is $5.29 and its 200 day simple moving average is $4.35. The stock has a market cap of $16.68 million, a P/E ratio of -4.18 and a beta of -0.14. Evoke Pharma, Inc. has a 1 year low of $1.94 and a 1 year high of $10.79.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.32). Evoke Pharma had a negative net margin of 42.07% and a negative return on equity of 99.48%. The company had revenue of $3.75 million for the quarter, compared to analysts’ expectations of $3.80 million.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on EVOK shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Evoke Pharma in a report on Wednesday, October 8th. Laidlaw lowered Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a report on Sunday, September 7th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. National Wealth Management Group LLC acquired a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned 5.14% of Evoke Pharma at the end of the most recent reporting period.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.